

# Neurophysiological Effects of Medication Tapering During Treatment With Spinal Cord Stimulation

NCT07413731

---

**Status** RECRUITING  
**Sponsor** Brai²n  
**Enrollment** 50 participants

## Key Eligibility Criteria

---

### Inclusion (9)

- Patient deemed a suitable candidate for SCS and routinely scheduled to undergo a trial phase with the Evoke SCS system.
- Diagnosis of Persistent Spinal Pain Syndrome Type 2 (lower spine).
- Current medication use:
- No strong opioids or anticonvulsants, or other analgesics
- Monotherapy with a strong opioid, or  
... and 4 more (see full listing online)

### Exclusion (6)

- Evidence of an active disruptive psychological or psychiatric disorder, or other condition significant enough to impact pain perception, compliance with intervention, or ability to evaluate outcomes (as determined by the investigator in consultation with a clinical psychologist).
- Current diagnosis of a progressive neurological disease such as multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, rapidly progressive arachnoiditis, rapidly progressive diabetic peripheral neuropathy, brain or spinal cord tumor, or severe/critical spinal stenosis.
- Current diagnosis or condition such as coagulation disorder, bleeding diathesis, platelet dysfunction, progressive peripheral vascular disease, or uncontrolled diabetes mellitus that presents excess risk for the procedure (as determined by the investigator).
- Active systemic or local infection.
- Pregnancy.  
... and 1 more (see full listing online)

## Locations (1 total)

---

Brai²n - ZAS Augustinus, Wilrijk, Belgium